A basic training course for those working on drug safety in the EU. This course has been designed to provide basic training and a good introduction to those concerned with veterinary pharmacovigilance.
This course has been designed to provide basic training and a good introduction to those concerned with veterinary pharmacovigilance. New entrants and support staff, as well as experienced personnel who require a better understanding of veterinary drug safety, will benefit from the practical guidance provided. Key terminology will be explained and roles and responsibilities will be clarified. There will be plenty of time for interaction and questions and answers to enable participants to get a good understanding of this complex subject.
Benefits of attending:
Gain an overview of the European regulatory framework n Be aware of Volume IXb
Learn about VICH
Understand adverse event reporting
Hear about causality assessment
Minimise the impact of data with errors
Know the requirements for periodic safety update reports
Get to grips with literature searches
Understand the implications of the proposed EU pharmacovigilance legislation and Brexit
Who Should Attend:
This course will be beneficial to those new to veterinary pharmacovigilance, support staff and experienced personnel who require a better understanding of drug safety in their current role. Adverse event monitoring and drug safety officers together with regulatory affairs and personnel from registration departments will also find this seminar useful.
Agenda:
Programme Day 1
What is pharmacovigilance?
Beneficial and harmful effects of veterinary medicinal products
Key definitions
The current regulatory framework and its global impact
Overview of the European regulatory framework, including Volume IXb and implications of the proposed EU pharmacovigilance legislation
Implications for the global environment - link to VICH
Practical applications of definitions
Adverse event reporting
Definitions
Impact of VICH guidelines
Expedited vs periodic
How to handle animal SARs
Handling human SARs
Understanding the wider scope of pharmacovigilance
Causality assessment
The principles of causality assessment with practical examples
Medical evaluation of individual reports of adverse events
The scheduled merits hearing dates, April 26 and 29, 2024, in the above-named matter will proceed by videoconference.
On April 26, 2024, the hearing will commence 11:15 a.m.
Members of the public may observe the hearing by videoconference, by...
Valeo Pharma Inc. ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the results of the matters submitted to shareholders at its annual meeting of shareholders held on April 25, 2024 (the "Meeting")....
Community Healthcare Trust Incorporated today announced that its Board of Directors has increased its common stock cash dividend for the quarter ended March 31, 2024. This dividend, in the amount of $0.46 per share, is payable on May 24, 2024 to...
DelveInsight's Urine Output Monitoring Systems Market Insights report provides the current and forecast market analysis, individual leading urine output monitoring systems companies' market...
Enghouse Video, a global leader in cutting-edge video technology solutions, today announced its partnership with SONIFI Health, enhancing virtual care in hospital settings.
SONIFI Health is a leading U.S. healthcare technology company based in Sioux...